Monte Rosa Therapeutics (GLUE) Financials

Monte Rosa Therapeutics logo
$9.06 -0.11 (-1.15%)
As of 12:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Monte Rosa Therapeutics

Annual Income Statements for Monte Rosa Therapeutics

This table shows Monte Rosa Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-44 -74 -108 -136 -73 -39
Consolidated Net Income / (Loss)
-36 -74 -109 -135 -73 -39
Net Income / (Loss) Continuing Operations
-44 -74 -109 -135 -73 -39
Total Pre-Tax Income
-36 -74 -109 -135 -70 -40
Total Operating Income
-28 -73 -112 -143 -81 -54
Total Gross Profit
0.00 0.00 0.00 0.00 76 124
Total Revenue
0.00 0.00 0.00 0.00 76 124
Operating Revenue
- - - 0.00 76 124
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
28 73 112 143 157 178
Selling, General & Admin Expense
4.01 16 27 32 35 36
Research & Development Expense
24 57 85 111 122 142
Total Other Income / (Expense), net
-7.87 -1.08 3.88 8.30 11 14
Interest & Investment Income
0.01 0.05 3.76 9.33 11 13
Other Income / (Expense), net
-7.88 -1.12 0.12 -0.91 0.42 1.54
Income Tax Expense
- - 0.00 0.34 2.57 -1.10
Basic Earnings per Share
($23.65) - ($2.30) ($2.63) ($0.98) ($0.46)
Weighted Average Basic Shares Outstanding
1.52M 25.00M 47.23M 51.40M 73.91M 83.07M
Diluted Earnings per Share
($23.65) - ($2.30) ($2.63) ($0.98) ($0.46)
Weighted Average Diluted Shares Outstanding
1.52M 25.00M 47.23M 51.40M 73.91M 83.07M
Weighted Average Basic & Diluted Shares Outstanding
1.52M 25.00M 49.36M 50.15M 61.51M 80.02M

Quarterly Income Statements for Monte Rosa Therapeutics

This table shows Monte Rosa Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-32 -30 -24 12 47 -12 -27 -47 -45 -44 3.06
Consolidated Net Income / (Loss)
-32 -30 -24 13 47 -12 -27 -46 -45 -43 3.06
Net Income / (Loss) Continuing Operations
-32 -30 -24 13 47 -12 -27 -46 -45 -43 3.06
Total Pre-Tax Income
-32 -30 -24 16 48 -11 -30 -46 -44 -43 3.78
Total Operating Income
-35 -33 -27 13 44 -16 -33 -50 -50 -49 -1.94
Total Gross Profit
1.06 4.70 9.22 61 85 23 13 2.78 4.21 8.97 54
Total Revenue
1.06 4.70 9.22 61 85 23 13 2.78 4.21 8.97 54
Operating Revenue
1.06 4.70 9.22 61 85 23 13 2.78 4.21 8.97 54
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
36 37 36 48 41 39 46 52 54 58 56
Selling, General & Admin Expense
8.99 9.28 8.13 8.78 8.70 8.10 9.07 11 10 10 11
Research & Development Expense
27 28 28 39 32 31 37 42 44 48 45
Total Other Income / (Expense), net
3.06 2.58 2.74 2.60 3.67 4.46 2.72 3.64 5.58 5.94 5.72
Interest & Investment Income
2.44 2.64 2.89 2.60 3.44 3.07 2.75 3.69 5.59 5.92 5.63
Other Income / (Expense), net
0.62 -0.05 -0.15 0.00 0.23 1.39 -0.03 -0.05 -0.01 0.03 0.09
Income Tax Expense
0.08 0.25 0.07 2.16 0.82 1.20 -3.18 0.06 0.05 0.21 0.72
Weighted Average Basic Shares Outstanding
60.16M 71.23M 82.01M 73.91M 82.15M 82.19M 82.40M 83.07M 99.88M 101.48M 101.79M
Weighted Average Diluted Shares Outstanding
60.16M 71.23M 82.01M 73.91M 82.96M 82.19M 82.40M 83.07M 99.88M 101.48M 108.62M
Weighted Average Basic & Diluted Shares Outstanding
50.51M 61.37M - 61.51M 61.51M 61.76M 65.12M 80.02M 84.48M 85.31M 85.45M

Annual Cash Flow Statements for Monte Rosa Therapeutics

This table details how cash moves in and out of Monte Rosa Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
34 309 -291 72 96 -94
Net Cash From Operating Activities
-23 -59 -92 -44 42 -23
Net Cash From Continuing Operating Activities
-23 -59 -92 -44 42 -23
Net Income / (Loss) Continuing Operations
-36 -74 -109 -135 -73 -39
Consolidated Net Income / (Loss)
-36 -74 -109 -135 -73 -39
Depreciation Expense
0.54 2.13 3.75 6.22 8.12 8.36
Non-Cash Adjustments To Reconcile Net Income
8.03 6.18 14 13 15 8.58
Changes in Operating Assets and Liabilities, net
4.26 6.29 -2.13 72 91 -1.11
Net Cash From Investing Activities
-3.39 -9.65 -219 89 -44 -102
Net Cash From Continuing Investing Activities
-3.39 -9.65 -219 89 -44 -102
Purchase of Property, Plant & Equipment
-3.39 -9.73 -13 -19 -3.99 -4.70
Purchase of Investments
- 0.00 -384 -103 -230 -377
Sale and/or Maturity of Investments
- 0.00 178 211 190 280
Net Cash From Financing Activities
60 378 20 27 99 30
Net Cash From Continuing Financing Activities
60 378 20 27 99 30
Repurchase of Common Equity
-0.44 -0.23 -0.36 -0.12 -0.64 -0.36
Issuance of Debt
- - - 0.00 47 0.00
Issuance of Common Equity
0.00 238 20 25 51 24
Other Financing Activities, net
0.00 0.15 0.78 2.61 1.59 6.46

Quarterly Cash Flow Statements for Monte Rosa Therapeutics

This table details how cash moves in and out of Monte Rosa Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-28 9.10 17 99 -146 -9.03 139 -78 30 -70 -45
Net Cash From Operating Activities
-38 -28 -21 129 -45 -35 100 -43 -37 -44 -41
Net Cash From Continuing Operating Activities
-38 -28 -21 129 -45 -35 100 -43 -37 -44 -41
Net Income / (Loss) Continuing Operations
-32 -30 -24 13 47 -12 -27 -46 -45 -43 3.06
Consolidated Net Income / (Loss)
-32 -30 -24 13 47 -12 -27 -46 -45 -43 3.06
Depreciation Expense
1.90 2.06 2.10 2.06 2.05 2.13 2.10 2.09 2.03 1.91 2.14
Non-Cash Adjustments To Reconcile Net Income
4.80 3.41 3.19 3.77 4.21 4.16 3.90 -3.68 12 5.00 -45
Changes in Operating Assets and Liabilities, net
-13 -2.93 -2.43 110 -99 -29 122 4.72 -6.86 -7.63 -0.98
Net Cash From Investing Activities
9.85 -61 38 -31 -100 25 38 -65 -261 -29 -4.54
Net Cash From Continuing Investing Activities
9.85 -61 38 -31 -100 25 38 -65 -261 -29 -4.54
Purchase of Property, Plant & Equipment
-1.38 -2.02 -0.40 -0.18 -1.59 -1.70 -0.65 -0.77 -1.87 -4.72 -1.56
Purchase of Investments
-56 -74 -32 -68 -138 -19 -66 -154 -332 -76 -92
Sale and/or Maturity of Investments
67 15 71 37 39 46 105 89 73 52 89
Net Cash From Financing Activities
0.25 98 0.02 0.61 0.01 0.37 0.35 30 328 3.21 0.57
Net Cash From Continuing Financing Activities
0.25 98 0.02 0.61 0.01 - 0.71 30 328 3.21 0.57
Other Financing Activities, net
0.25 0.42 0.02 0.61 0.01 - 0.71 5.73 4.04 3.21 0.57

Annual Balance Sheets for Monte Rosa Therapeutics

This table presents Monte Rosa Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
49 366 342 304 439 449
Total Current Assets
44 349 276 236 377 393
Cash & Equivalents
42 346 55 128 224 130
Short-Term Investments
- 0.00 208 104 148 247
Accounts Receivable
- 0.00 7.66 0.51 0.17 4.60
Prepaid Expenses
1.89 2.60 4.44 3.29 5.12 4.48
Other Current Assets
- - - - 0.00 7.00
Plant, Property, & Equipment, net
4.62 12 27 34 29 26
Total Noncurrent Assets
1.16 5.34 39 34 32 29
Other Noncurrent Operating Assets
1.16 5.34 39 34 32 29
Total Liabilities & Shareholders' Equity
49 366 342 304 439 449
Total Liabilities
30 19 71 125 216 216
Total Current Liabilities
29 17 26 47 157 64
Accounts Payable
9.60 17 22 26 36 30
Current Deferred Revenue
- - 0.00 18 117 30
Other Current Liabilities
20 0.00 3.13 3.16 3.71 4.40
Total Noncurrent Liabilities
1.07 2.18 45 78 59 151
Noncurrent Deferred Revenue
- - 0.00 32 16 111
Noncurrent Employee Benefit Liabilities
1.07 2.18 1.53 2.71 3.70 5.27
Other Noncurrent Operating Liabilities
- 0.00 44 43 39 35
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-49 348 271 179 223 233
Total Preferred & Common Equity
49 348 271 179 223 233
Preferred Stock
- - 0.00 0.00 0.00 0.00
Total Common Equity
-49 348 271 179 223 233
Common Stock
0.41 472 504 548 665 714
Retained Earnings
-48 -122 -231 -366 -439 -477
Accumulated Other Comprehensive Income / (Loss)
-1.06 -2.02 -1.75 -2.72 -3.36 -3.83

Quarterly Balance Sheets for Monte Rosa Therapeutics

This table presents Monte Rosa Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
279 252 267 344 315 393 360 460 736 691 698
Total Current Assets
208 183 199 278 251 332 299 402 678 631 640
Cash & Equivalents
47 59 100 109 126 79 69 208 160 90 45
Short-Term Investments
156 119 93 153 117 248 221 183 506 531 533
Accounts Receivable
1.15 0.29 0.60 9.84 0.60 1.41 2.37 4.97 4.61 4.92 7.62
Prepaid Expenses
3.88 4.14 5.54 5.85 8.43 4.80 6.50 5.59 6.72 5.38 4.72
Other Current Assets
- - - - - - - - 0.00 0.00 50
Plant, Property, & Equipment, net
35 35 34 33 31 29 29 28 28 30 29
Total Noncurrent Assets
35 34 34 33 32 32 31 30 30 30 29
Other Noncurrent Operating Assets
35 34 34 33 32 32 31 30 30 30 29
Total Liabilities & Shareholders' Equity
279 252 267 344 315 393 360 460 736 691 698
Total Liabilities
65 68 114 119 110 118 92 214 215 204 202
Total Current Liabilities
19 23 41 42 42 59 42 61 71 60 62
Accounts Payable
16 20 18 19 19 23 19 32 33 33 37
Current Deferred Revenue
- - 20 20 19 33 18 25 33 22 21
Other Current Liabilities
2.67 2.88 3.35 3.47 3.65 3.87 4.09 4.24 4.48 4.63 4.19
Total Noncurrent Liabilities
46 45 73 77 68 59 50 153 143 144 139
Noncurrent Deferred Revenue
- - 29 34 25 17 8.06 112 104 106 102
Noncurrent Employee Benefit Liabilities
1.51 1.45 2.57 2.61 2.82 3.96 4.56 4.74 5.26 5.24 5.13
Other Noncurrent Operating Liabilities
44 44 42 41 40 38 37 36 35 33 32
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
214 185 153 225 205 275 268 246 522 487 496
Total Preferred & Common Equity
214 185 153 225 205 275 268 246 522 487 496
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
214 185 153 225 205 275 268 246 522 487 496
Common Stock
513 519 553 656 660 670 675 680 1,048 1,058 1,064
Retained Earnings
-298 -333 -398 -428 -452 -392 -404 -431 -522 -565 -562
Accumulated Other Comprehensive Income / (Loss)
-1.64 -1.46 -2.69 -2.67 -2.32 -3.33 -3.37 -3.25 -4.75 -5.17 -6.19

Annual Metrics And Ratios for Monte Rosa Therapeutics

This table displays calculated financial ratios and metrics derived from Monte Rosa Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 46,505,914.00 48,399,056.00 50,081,023.00 - 65,117,761.00
DEI Adjusted Shares Outstanding
0.00 46,505,914.00 48,399,056.00 50,081,023.00 - 65,117,761.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -1.59 -2.24 -2.72 - -0.60
Growth Metrics
- - - - - -
Profitability Metrics
- - - - - -
Net Operating Profit after Tax (NOPAT)
-20 -51 -79 -100 -57 -38
Return On Investment Capital (ROIC_SIMPLE)
- - - -55.97% -25.47% -16.28%
Earnings before Interest and Taxes (EBIT)
-36 -74 -112 -144 -81 -53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-35 -72 -109 -138 -73 -44
Valuation Ratios
- - - - - -
Leverage & Solvency
- - - - - -
Liquidity Ratios
- - - - - -
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -75 -85 -40 39 -43
Efficiency Ratios
- - - - - -
Capital & Investment Metrics
- - - - - -
Invested Capital
-23 1.44 7.63 -53 -149 -144
Increase / (Decrease) in Invested Capital
0.00 24 6.18 -61 -96 5.17
Book Value per Share
($32.12) $7.47 $5.61 $3.58 $3.02 $3.58
Tangible Book Value per Share
($32.12) $7.47 $5.61 $3.58 $3.02 $3.58
Total Capital
19 348 271 179 223 233
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-42 -346 -264 -232 -372 -377
Capital Expenditures (CapEx)
3.39 9.65 13 19 3.99 4.70
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-27 -14 -13 -43 -152 -48
Debt-free Net Working Capital (DFNWC)
14 332 250 190 220 329
Net Working Capital (NWC)
14 332 250 190 220 329
Net Nonoperating Expense (NNE)
16 23 30 35 16 0.68
Net Nonoperating Obligations (NNO)
-42 -346 -264 -232 -372 -377
Total Depreciation and Amortization (D&A)
0.54 2.13 3.75 6.22 8.12 8.36
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($2.96) $0.00 ($2.63) ($0.98) ($0.46)
Adjusted Weighted Average Basic Shares Outstanding
0.00 46.63M 47.23M 51.40M 73.91M 83.07M
Adjusted Diluted Earnings per Share
$0.00 ($2.96) $0.00 ($2.63) ($0.98) ($0.46)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 46.63M 47.23M 51.40M 73.91M 83.07M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($2.96) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 25.00M 49.36M 50.15M 61.51M 80.02M
Normalized Net Operating Profit after Tax (NOPAT)
-20 -51 -79 -100 -57 -38
Debt Service Ratios
- - - - - -
Payout Ratios
- - - - - -

Quarterly Metrics And Ratios for Monte Rosa Therapeutics

This table displays calculated financial ratios and metrics derived from Monte Rosa Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
50,154,073.00 50,512,019.00 61,372,824.00 - 61,509,821.00 61,509,821.00 61,759,350.00 65,117,761.00 80,015,667.00 84,479,418.00 85,313,401.00
DEI Adjusted Shares Outstanding
50,154,073.00 50,512,019.00 61,372,824.00 - 61,509,821.00 61,509,821.00 61,759,350.00 65,117,761.00 80,015,667.00 84,479,418.00 85,313,401.00
DEI Earnings Per Adjusted Shares Outstanding
-0.64 -0.60 -0.38 - 0.76 -0.20 -0.44 -0.72 -0.57 -0.52 0.04
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 7,882.05% 394.01% 38.54% - -95.04% -61.33% 325.80%
EBITDA Growth
2.68% 14.66% 29.99% 144.76% 242.82% 60.70% -25.76% - -203.66% -291.98% 100.96%
EBIT Growth
0.43% 12.32% 27.78% 136.63% 228.96% 56.68% -23.70% - -213.04% -246.69% 94.41%
NOPAT Growth
-2.01% 12.30% 28.24% 145.89% 276.91% 52.35% -24.31% - -180.93% -215.87% 93.19%
Net Income Growth
0.22% 13.84% 31.60% 140.41% 246.66% 59.44% -13.50% - -194.92% -252.96% 111.31%
EPS Growth
18.46% 39.44% 58.57% 147.37% 207.55% 65.12% -13.79% - -178.95% -186.67% 0.00%
Operating Cash Flow Growth
-63.06% -9.65% 15.02% 335.05% -19.20% -25.04% 578.37% - 17.86% -27.06% -140.80%
Free Cash Flow Firm Growth
202.44% 187.94% 273.63% 194.76% 99.76% -202.51% 253.65% - 8.45% 396.89% -176.48%
Invested Capital Growth
-465.96% -454.50% -707.39% -180.67% -26.11% 40.02% -295.93% - -183.43% -494.40% 43.94%
Revenue Q/Q Growth
0.00% 341.26% 96.29% 558.06% 40.04% -72.69% -44.95% - 51.38% 113.02% 506.22%
EBITDA Q/Q Growth
3.67% 5.54% 19.77% 161.31% 207.40% -125.99% -156.74% - -0.70% 1.71% 100.63%
EBIT Q/Q Growth
3.33% 4.75% 18.40% 148.75% 240.37% -132.00% -133.01% - -0.56% 1.87% 96.24%
NOPAT Q/Q Growth
-0.24% 6.60% 18.73% 160.32% 286.40% -125.16% -112.00% - -0.64% 1.81% 95.43%
Net Income Q/Q Growth
3.86% 5.19% 21.28% 156.32% 248.92% -126.22% -120.26% - 3.54% 2.49% 107.06%
EPS Q/Q Growth
7.02% 18.87% 32.56% 193.10% 111.11% -126.32% -120.00% - 18.18% 4.44% 0.00%
Operating Cash Flow Q/Q Growth
-228.79% 27.24% 24.39% 714.09% -135.29% 23.68% 389.25% - 13.12% -18.05% 7.11%
Free Cash Flow Firm Q/Q Growth
-25.95% -6.20% -4.22% 343.05% -49.82% -148.14% 430.44% - 246.04% 31.79% -185.12%
Invested Capital Q/Q Growth
24.06% 7.03% 2.14% -306.25% 65.88% 55.78% -545.91% - -0.18% 7.26% 39.09%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
EBITDA Margin
-3,047.93% -652.50% -266.68% 24.84% 54.54% -51.91% -242.08% - -1,140.45% -526.22% 0.55%
Operating Margin
-3,284.49% -695.25% -287.84% 21.44% 51.85% -67.06% -258.26% - -1,188.46% -547.84% -3.57%
EBIT Margin
-3,226.22% -696.38% -289.50% 21.45% 52.12% -61.07% -258.49% - -1,188.65% -547.56% -3.40%
Profit (Net Income) Margin
-3,004.51% -645.58% -258.89% 22.16% 55.20% -53.01% -212.10% - -1,057.08% -483.91% 5.63%
Tax Burden Percent
100.26% 100.84% 100.30% 86.13% 98.28% 110.81% 89.50% - 100.12% 100.48% 81.05%
Interest Burden Percent
92.89% 91.93% 89.16% 119.95% 107.77% 78.34% 91.68% - 88.83% 87.95% -204.71%
Effective Tax Rate
0.00% 0.00% 0.00% 13.87% 1.72% 0.00% 0.00% - 0.00% 0.00% 18.95%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)
-68.28% -59.51% -61.23% -36.15% 2.88% 9.81% 9.28% - -32.62% -42.66% -35.30%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-11.92% -12.88% -15.29% 4.37% 25.19% -30.89% -121.11% - -90.39% -29.94% -0.41%
Return on Assets (ROA)
-11.10% -11.94% -13.67% 4.51% 26.68% -26.82% -99.38% - -80.39% -26.46% 0.68%
Return on Common Equity (ROCE)
-68.28% -59.51% -61.23% -36.15% 2.88% 9.81% 9.28% - -32.62% -42.66% -35.30%
Return on Equity Simple (ROE_SIMPLE)
-88.70% 0.00% 0.00% 0.00% 2.24% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-24 -23 -19 11 43 -11 -23 -35 -35 -34 -1.57
NOPAT Margin
-2,299.14% -486.68% -201.49% 18.47% 50.96% -46.94% -180.78% - -831.92% -383.49% -2.89%
Net Nonoperating Expense Percent (NNEP)
-3.53% -3.21% -2.52% 0.74% 1.39% -0.51% -1.26% - -1.91% -1.98% 0.96%
Return On Investment Capital (ROIC_SIMPLE)
-16.04% -10.17% -9.04% 5.02% 15.73% -4.06% -9.39% -14.93% -6.71% -7.06% -0.32%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
844.45% 197.70% 88.18% 14.47% 10.25% 34.90% 71.00% - 241.69% 113.00% 20.13%
R&D to Revenue
2,540.04% 597.55% 299.65% 64.09% 37.90% 132.16% 287.27% - 1,046.77% 534.84% 83.44%
Operating Expenses to Revenue
3,384.49% 795.25% 387.84% 78.56% 48.15% 167.06% 358.26% - 1,288.46% 647.84% 103.57%
Earnings before Interest and Taxes (EBIT)
-34 -33 -27 13 44 -14 -33 -50 -50 -49 -1.85
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-32 -31 -25 15 46 -12 -31 -48 -48 -47 0.30
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.32 0.84 1.58 1.91 1.04 1.03 1.86 - 2.52 4.20 2.05
Price to Tangible Book Value (P/TBV)
2.32 0.84 1.58 1.91 1.04 1.03 1.86 - 2.52 4.20 2.05
Price to Revenue (P/Rev)
332.32 32.80 21.72 5.63 1.79 1.56 2.52 - 30.64 71.17 14.47
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 51.73 11.82 22.86 - 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 1.93% 8.46% 4.37% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
151.03 0.00 5.55 0.71 0.00 0.00 0.37 - 15.13 49.55 6.26
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 3.60 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 6.57 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 8.17 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 1.28 0.00 0.00 0.45 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 1.37 0.00 0.00 0.57 - 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Financial Leverage
-1.07 -1.06 -1.08 -1.50 -1.21 -1.12 -1.40 - -1.24 -1.21 -1.31
Leverage Ratio
1.45 1.42 1.45 1.85 1.54 1.43 1.72 - 1.42 1.39 1.56
Compound Leverage Factor
1.35 1.31 1.30 2.21 1.66 1.12 1.57 - 1.26 1.22 -3.19
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Altman Z-Score
0.06 -0.27 0.34 0.66 1.67 1.47 1.02 - 3.51 5.67 2.99
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.82 6.56 6.03 2.40 5.61 7.16 6.54 - 9.54 10.58 10.32
Quick Ratio
4.69 6.42 5.83 2.37 5.53 7.00 6.45 - 9.44 10.49 9.43
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
27 25 24 107 54 -26 86 -40 58 77 -65
Operating Cash Flow to CapEx
-2,757.59% -1,373.24% -5,261.65% 70,449.18% -2,866.54% -2,048.38% 15,426.73% - -2,000.48% -934.03% -2,630.17%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.02 0.05 0.20 0.48 0.51 0.47 - 0.08 0.05 0.12
Accounts Receivable Turnover
0.77 1.05 33.69 223.07 158.77 29.15 65.30 - 14.28 7.88 11.17
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover
0.03 0.17 0.45 2.39 5.03 5.71 6.15 - 1.49 0.97 2.50
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)
475.29 348.46 10.83 1.64 2.30 12.52 5.59 - 25.57 46.31 32.67
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
475.29 348.46 10.83 1.64 2.30 12.52 5.59 - 25.57 46.31 32.67
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-40 -38 -37 -149 -51 -23 -145 -144 -144 -134 -82
Invested Capital Turnover
-0.07 -0.43 -0.98 -0.75 -3.49 -5.93 -1.99 - -0.44 -0.37 -0.62
Increase / (Decrease) in Invested Capital
-51 -48 -43 -96 -11 15 -109 5.17 -93 -111 64
Enterprise Value (EV)
161 -73 83 54 -41 -13 66 - 650 1,423 440
Market Capitalization
354 189 325 426 285 277 458 - 1,316 2,044 1,018
Book Value per Share
$3.04 $4.45 $3.35 $3.02 $4.47 $4.36 $3.98 $3.58 $6.52 $5.77 $5.82
Tangible Book Value per Share
$3.04 $4.45 $3.35 $3.02 $4.47 $4.36 $3.98 $3.58 $6.52 $5.77 $5.82
Total Capital
153 225 205 223 275 268 246 233 522 487 496
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-193 -262 -242 -372 -326 -291 -391 -377 -666 -621 -578
Capital Expenditures (CapEx)
1.38 2.02 0.40 0.18 1.59 1.70 0.65 0.77 1.87 4.72 1.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-35 -27 -33 -152 -53 -33 -51 -48 -60 -49 0.29
Debt-free Net Working Capital (DFNWC)
158 236 210 220 273 258 340 329 607 572 578
Net Working Capital (NWC)
158 236 210 220 273 258 340 329 607 572 578
Net Nonoperating Expense (NNE)
7.51 7.46 5.29 -2.24 -3.61 1.41 4.00 11 9.48 9.01 -4.63
Net Nonoperating Obligations (NNO)
-193 -262 -242 -372 -326 -291 -391 -377 -666 -621 -578
Total Depreciation and Amortization (D&A)
1.90 2.06 2.10 2.06 2.05 2.13 2.10 2.09 2.03 1.91 2.14
Debt-free, Cash-free Net Working Capital to Revenue
-3,303.48% -462.88% -217.83% -200.54% -33.24% -18.53% -28.03% - -139.01% -171.81% 0.42%
Debt-free Net Working Capital to Revenue
14,825.47% 4,090.09% 1,399.44% 291.57% 171.21% 144.74% 187.49% - 1,412.03% 1,990.28% 821.93%
Net Working Capital to Revenue
14,825.47% 4,090.09% 1,399.44% 291.57% 171.21% 144.74% 187.49% - 1,412.03% 1,990.28% 821.93%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.53) ($0.43) ($0.29) $0.27 $0.57 ($0.15) ($0.33) ($0.55) ($0.45) ($0.43) $0.00
Adjusted Weighted Average Basic Shares Outstanding
60.16M 71.23M 82.01M 73.91M 82.15M 82.19M 82.40M 83.07M 99.88M 101.48M 101.79M
Adjusted Diluted Earnings per Share
($0.53) ($0.43) ($0.29) $0.27 $0.57 ($0.15) ($0.33) ($0.55) ($0.45) ($0.43) $0.00
Adjusted Weighted Average Diluted Shares Outstanding
60.16M 71.23M 82.01M 73.91M 82.96M 82.19M 82.40M 83.07M 99.88M 101.48M 108.62M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
50.51M 61.37M 0.00 61.51M 61.51M 61.76M 65.12M 80.02M 84.48M 85.31M 85.45M
Normalized Net Operating Profit after Tax (NOPAT)
-24 -23 -19 11 43 -11 -23 -35 -35 -34 -1.57
Normalized NOPAT Margin
-2,299.14% -486.68% -201.49% 18.47% 50.96% -46.94% -180.78% - -831.92% -383.49% -2.89%
Pre Tax Income Margin
-2,996.71% -640.21% -258.12% 25.72% 56.17% -47.84% -236.98% - -1,055.84% -481.59% 6.95%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -0.58% -0.63% -0.88% 10.42% 0.00% 0.00% - -0.27% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Monte Rosa Therapeutics’ (NASDAQ:GLUE) latest statements show a well-funded but still loss-making biotechnology company. Revenue increased sequentially in the second quarter of 2026, but operating expenses remain substantially higher than revenue. The company’s balance sheet provides meaningful liquidity, although cash continues to be consumed by research and development activities.

  • Strong liquidity: Monte Rosa ended Q2 2026 with $90.1 million in cash and $531.0 million in short-term investments, or approximately $621.1 million in readily available funds. Total current assets were $631.4 million, compared with $59.7 million in current liabilities.
  • Revenue improved sequentially: Q2 2026 revenue rose to $9.0 million from $4.2 million in Q1 2026, an increase of roughly 113%. The company has generated revenue in each quarter provided since Q1 2024, although the amounts have been highly variable.
  • Investment income is supporting results: Interest and investment income increased to $5.9 million in Q2 2026 from $5.6 million in Q1 and $3.7 million in Q4 2025. The company’s large investment portfolio is providing an important offset to operating losses.
  • Research spending is being maintained at a high level: Research and development expense reached $48.0 million in Q2 2026, up from $44.1 million in Q1. While this increases near-term losses, continued investment may support advancement of Monte Rosa’s clinical pipeline.
  • Equity remains positive: Total shareholders’ equity was $487.3 million at June 30, 2026, substantially exceeding total liabilities of $203.9 million. This gives the company a sizeable capital base relative to its obligations.
  • Liquidity declined during the quarter: Cash and short-term investments totaled approximately $621.1 million at the end of Q2, down from $666.2 million at the end of Q1. The decline reflects operating and investing cash outflows, despite a $24.6 million increase in short-term investments.
  • Revenue remains unpredictable: Quarterly revenue ranged from zero in Q2 2023 to $84.9 million in Q1 2025, before falling to $4.2 million in Q1 2026 and recovering to $9.0 million in Q2. Investors should not assume that the latest sequential increase represents a stable growth trend.
  • Operating losses remain significant: Q2 2026 operating expenses totaled $58.1 million against $9.0 million of revenue, producing an operating loss of $49.1 million. The company reported a net loss attributable to common shareholders of $43.8 million, or $0.43 per share.
  • Operating cash burn is persistent: Net cash used in operating activities was $44.1 million in Q2 2026, compared with $37.4 million in Q1 and $43.0 million in Q4 2025. Monte Rosa has generally reported negative operating cash flow across the provided quarters, indicating continued dependence on its cash reserves and financing activities.
  • Recent financing included substantial debt: The company recorded $324.3 million of debt issuance in Q1 2026. Although this improved liquidity at the time, it also introduces additional financial obligations and may increase risk if operating losses persist.

At the Q2 operating cash-burn rate, the company’s approximately $621 million of cash and short-term investments could provide considerable funding capacity, potentially equivalent to several years of liquidity. However, that estimate is sensitive to clinical spending, milestone payments, revenue timing, investment returns and future financing needs. The key issues for investors are whether revenue can become more consistent and whether Monte Rosa can advance its pipeline before its cash reserves are materially depleted.

11/17/26 12:38 PM ETAI Generated. May Contain Errors.

Monte Rosa Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Monte Rosa Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

In the past 5 years, Monte Rosa Therapeutics' net income has ranged from -$135.35 million in 2023 to -$35.88 million in 2020, and is currently -$38.63 million as of their latest financial filing in 2025. See where experts think Monte Rosa Therapeutics is headed by visiting Monte Rosa Therapeutics' forecast page.

Monte Rosa Therapeutics' total operating income in 2025 was -$54.21 million, based on the following breakdown:
  • Total Gross Profit: $123.67 million
  • Total Operating Expenses: $177.88 million

Over the last 5 years, Monte Rosa Therapeutics' total revenue changed from $0.00 in 2020 to $123.67 million in 2025, a change of 12,367,200,000.0%.

In the past 13 quarters, Monte Rosa Therapeutics' cash and equivalents has ranged from $45.18 million in Q3 2026 to $208.34 million in Q3 2025, and is currently $45.18 million as of their latest financial filing in Q3 2026.

Monte Rosa Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2020.

Over the last 5 years, Monte Rosa Therapeutics' book value per share changed from -32.12 in 2020 to 3.58 in 2025.



Financial statements for NASDAQ:GLUE last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners